WEKO3
アイテム
Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan
http://hdl.handle.net/2241/0002002478
http://hdl.handle.net/2241/0002002478e995f07e-a573-4fe9-aade-0e21d56d514b
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
CTRO_29-54.pdf (506 KB)
|
.png)
|
| Item type | Journal Article(1) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2022-01-14 | |||||||||||||||||||||||||||||||
| タイトル | ||||||||||||||||||||||||||||||||
| タイトル | Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan | |||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||
| 言語 | ||||||||||||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||||||||||||
| アクセス権 | ||||||||||||||||||||||||||||||||
| アクセス権 | open access | |||||||||||||||||||||||||||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||||||||||||||||||||||||||
| 著者 |
Oshiro, Yoshiko
× Oshiro, Yoshiko
× 水本, 斉志
WEKO
181032
× Sekino, Yuta
× Maruo, Kazushi
× Ishida, Toshiki
× Sumiya, Taisuke
× Nakamura, Masatoshi
× Ohkawa, Ayako
× Takizawa, Daichi
× Okumura, Toshiyuki
× Tamaki, Yoshio
× 櫻井, 英幸 |
|||||||||||||||||||||||||||||||
| 抄録 | ||||||||||||||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||||||||||||||
| 内容記述 | Objectives To estimate appropriate dose-volume parameters for avoidance of pneumonitis in use of chemoradiotherapy and durvalumab for treatment of lung cancer. Materials and methods Patients with non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab at 9 centers were enrolled in the study. Three-dimensional radiotherapy, intensity modulated radiotherapy, and proton beam therapy were used. The frequency and severity of pneumonitis and the dose-volume relationship for normal lung were evaluated. Univariable and multivariable analyses were conducted to identify risk factors. A covariate adjusted hazard ratio was then estimated for the percentages of normal lung volume irradiated at ≥ X Gy (Vx) (X = 5–40) and lung volume non-irradiated at ≥ X Gy (X = 5–40), with the covariates selected in the variable selection. Cumulative incidence functions and covariate adjusted hazard ratios were also estimated for dichotomized variables, with estimated cut-off points. Results A total of 91 patients were enrolled in the study. The median time from the start of radiotherapy to development of pneumonitis was 4.1 months. Pneumonitis was observed in 80 patients (88%), including grade 2 or severe pneumonitis in 31 (34%) and ≥ grade 3 pneumonitis in 11 (12%). Pneumonitis was inside the irradiation field in 73 of the 80 patients (91%). The selected factors for ≥ grade 2 pneumonitis were V20, and primary site (upper lobe) in multivariable analysis. The cut off value of V20 was 18.99%, and there was a significant difference between V20 of < 18.77 and ≥ 18.77. Conclusion Though there are some limitation of this study, the basic concept of concurrent chemoradiotherapy with an emphasis on V20 remains unchanged in use of durvalumab. However, we recommend reduction of V20 to as small a value as possible in use of this therapy. |
|||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||
| 書誌情報 |
en : Clinical and Translational Radiation Oncology 巻 29, p. 54-59, 発行日 2021-07 |
|||||||||||||||||||||||||||||||
| ISSN | ||||||||||||||||||||||||||||||||
| 収録物識別子タイプ | EISSN | |||||||||||||||||||||||||||||||
| 収録物識別子 | 24056308 | |||||||||||||||||||||||||||||||
| DOI | ||||||||||||||||||||||||||||||||
| 関連タイプ | isIdenticalTo | |||||||||||||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||||||||||||||
| 関連識別子 | https://doi.org/10.1016/j.ctro.2021.05.009 | |||||||||||||||||||||||||||||||
| PMID | ||||||||||||||||||||||||||||||||
| 識別子タイプ | PMID | |||||||||||||||||||||||||||||||
| 関連識別子 | 34151033 | |||||||||||||||||||||||||||||||
| 権利情報 | ||||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||
| 権利情報 | © 2021 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. | |||||||||||||||||||||||||||||||
| 権利情報 | ||||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||
| 権利情報 | This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/). | |||||||||||||||||||||||||||||||
| 出版タイプ | ||||||||||||||||||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||||||||||
| 出版者 | Elsevier | |||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||
